Massachusetts Society of Clinical Oncologists - FDA has approved a new indication for IMFINZI® (durvalumab), in combination with IMJUDO® (tremelimumab-actl), for unresectable HCC

"The Voice of Oncology in Massachusetts"

FDA has approved a new indication for IMFINZI® (durvalumab), in combination with IMJUDO® (tremelimumab-actl), for unresectable HCC

October 24, 2022 10:14 AM | Katy Monaco (Administrator)

Food and Drug Administration approved IMJUDO® (tremelimumab-actl), (AstraZeneca Pharmaceuticals) in combination with IMFINZI® (durvalumab) for adult patients with unresectable hepatocellular carcinoma (uHCC). Read More.

Please see Full Prescribing Information including Medication Guide for IMFINZI and IMJUDO. You may report side effects related to AstraZeneca products by clicking here.

ADDRESS

860 Winter Street, Waltham, MA, 02451

tel: 781.434.7329

msco@mms.org

Home
About
Advocacy
Membership
Events
Resources

Join Our Mailing List